希罗达联合泰素帝治疗晚期胃癌的疗效观察

The Clinical Observation of Xeloda Combined with Taxotere in the Treatment of Advanced Gastric Cancer

目的观察希罗达联合泰素帝方案治疗晚期胃癌的疗效与毒副反应。方法38例晚期胃癌均给予希罗达1 250 mg/m2,2次/d口服,d1～14;泰素帝75 mg/m2,静滴,d1,8。21 d为1周期,化疗2周期后按WHO标准评定疗效及毒副反应。结果38例中CR1例,PR 19例,SD 12例,PD 6例,总有效率(RR)52.6%。主要毒副反应为骨髓抑制、手足综合征和消化道反应。结论希罗达联合泰素帝治疗晚期胃癌有较好疗效,毒副反应轻,患者可耐受。

Objective To evaluate the efficacy and adverse reaction of xeloda combined with taxotere chemotherapy in the treatment of advanced gastric cancer（AGC）.Methods The 38 patients with AGC treated with xeloda 1 250 mg/m2,twice a day,14 days totally and taxotere 75 mg/m2,intravenaus drip,divided into d1,8.The efficacy and adverse reaction were evaluated after two weeks of the completion of chemotherapy according to the WHO criterion.Results Among 38 patients studied,CR 1,PR 19,SD 12,and PD 6.The total response rate was 52.6%.The main side effects were supperssion of bone marrow,hand-foot syndrome,and gastroenteric discomfort.Conclusion The combination of xeloda and taxotere is safe and effective therapy for the patients with AGC.